Yue Bei, Yu Zhi-Lun, Lv Cheng, Geng Xiao-Long, Wang Zheng-Tao, Dou Wei
The MOE key Laboratory of Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, and the SATCM key Laboratory of New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
World J Gastroenterol. 2020 Aug 14;26(30):4378-4393. doi: 10.3748/wjg.v26.i30.4378.
The rapid development of metagenomics, metabolomics, and metatranscriptomics provides novel insights into the intestinal microbiota factors linked to inflammatory bowel disease (IBD). Multiple microorganisms play a role in intestinal health; these include bacteria, fungi, and viruses that exist in a dynamic balance to maintain mucosal homeostasis. Perturbations in the intestinal microbiota disrupt mucosal homeostasis and are closely related to IBD in humans and colitis in mice. Therefore, preventing or correcting the imbalance of microbiota may serve as a novel prevention or treatment strategy for IBD. We review the most recent evidence for direct or indirect interventions targeting intestinal microbiota for treatment of IBD in order to overcome the current limitations of IBD therapies and shed light on personalized treatment options.
宏基因组学、代谢组学和宏转录组学的快速发展为与炎症性肠病（IBD）相关的肠道微生物群因素提供了新的见解。多种微生物在肠道健康中发挥作用；这些微生物包括细菌、真菌和病毒，它们以动态平衡的状态存在以维持黏膜稳态。肠道微生物群的紊乱会破坏黏膜稳态，并与人类的IBD和小鼠的结肠炎密切相关。因此，预防或纠正微生物群的失衡可能成为IBD的一种新的预防或治疗策略。我们综述了针对肠道微生物群进行直接或间接干预以治疗IBD的最新证据，以便克服IBD治疗的当前局限性，并为个性化治疗方案提供思路。
